CG Oncology, Inc. (CGON) Goldman Sachs forty seventh Annual World Healthcare Convention 2026 June 9, 2026 2:40 PM EDT
Firm Members
Arthur Kuan – Chairman, President & CEO
Convention Name Members
Corinne Jenkins – Goldman Sachs Group, Inc., Analysis Division
Presentation
Corinne Jenkins
Goldman Sachs Group, Inc., Analysis Division
All proper. Good afternoon, everybody, and thanks for becoming a member of us right here on the Goldman Sachs World Healthcare Convention. Thrilled to be joined on stage right this moment with Arthur from CG Oncology, Chief Government Officer. I’ll flip it to you first to simply sort of introduce the corporate and speak about what you consider as key worth drivers over the subsequent 12 to 24 months.
Arthur Kuan
Chairman, President & CEO
Positive. So we’re an organization that is laser-focused on creating our oncolytic immunotherapy, cretostimogene, for sufferers with each intermediate threat in addition to high-risk non-muscle-invasive bladder most cancers. And now we have quite a few catalysts arising. Most significantly, now we have a Part III randomized managed trial known as PIVOT-006. Its outcomes will come within the coming months. Shortly thereafter, we’re guiding to finish our [indiscernible] setting. And actually in direction of the again half of this 12 months, there shall be extra knowledge round sturdiness of our product within the BCG unresponsive setting in addition to once we mix it with gemcitabine, extra sturdiness updates shall be accessible as nicely.
Query-and-Reply Session
Corinne Jenkins
Goldman Sachs Group, Inc., Analysis Division
Nice. So perhaps let’s begin sort of on the highest degree. As you have a look at the non-muscle-invasive bladder most cancers class, are you able to speak about the way you see the unmet want and the way sufferers are sort of stratified inside that indication?
Arthur Kuan
Chairman, President & CEO
Positive. So typically, bladder most cancers is cut up into each non-muscle-invasive bladder most cancers, which is about 80% of the chance and 20% are
